Change in substantial holding

Sep 25, 2026 at 4:06 AM EDT · Issued by Telix Pharmaceuticals Limited via ASX

Filed with ASX · Sep 25, 2026 at 4:06 AM EDT

On 6ix: 6ix.com/news/change-in-substantial-holding-944

604 Page 1 25-Sep-2026To Company Name/SchemeACN/ARSN1. Details of substantial holder (1)NameACN/ARSN (if applicable)There was a change in the interests of the 23/09/2026substantial holder onThe previous notice was given to the company on08/07/2026The previous notice was dated06/07/20262....

View Attachment

6ix hasn’t read this filing yet.

Telix Pharmaceuticals Limited on 6ix

Earlier from Telix Pharmaceuticals

Appendix 3Y Change in Director Interest-D GillSep 25
Application for quotation of securities - TLXSep 25
Grant of waivers of Listing Rule 7.3.4Sep 21
Telix and ITM Join Forces to Create a Radiopharmaceutical PowerhouseSep 20
Telix and ITM Join Forces to Create Radiopharma PowerhouseSep 20

Later from Telix Pharmaceuticals

FDA Fast Track for BiPASS Pre Biopsy Prostate ImagingSep 29
Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer ImagingSep 29
Notification regarding unquoted securities - TLXOct 4
Notification of cessation of securities - TLXOct 4
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)Oct 6

All Telix Pharmaceuticals news releases